Michael Cottler is a partner in the firm's Litigation Department, where he focuses his practice on intellectual property, with a concentration on patent issues in the areas of biotechnology, pharmaceuticals (small molecules and biologics), consumer products and medical devices. He has tried a number of complex patent litigations, particularly Hatch-Waxman/ANDA cases, relating to chemical agents and pharmaceutical products across a spectrum of medical indications. He joined Goodwin in 2006.





Mr. Cottler advises clients in the pharmaceutical, biotechnology, and other industries on a number of intellectual property matters. His experience includes patent litigation, client counseling (including invalidity and clearance opinions), due diligence, patent prosecution strategy, and IP licensing disputes. Mr. Cottler has extensive experience handling all aspects of patent litigation, including overseeing fact and expert discovery, examining trial witnesses, preparing pretrial motions and briefs, and arguing in Court relating to discovery disputes, claim construction, Daubert motions, and motions in limine. The following are a representation of Mr. Cottler’s matters:

  • Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 1:14-cv-01309 (D. Del.) (Hatch-Waxman litigation regarding Actavis’ generic Quillivant® (liquid, extended-release methylphenidate), case now on remand after appeal).
  • Novartis Pharmaceuticals Corp., et al., v. West-Ward Pharmaceuticals International Ltd., No. 15-cv-00474 (D. Del.) (Hatch-Waxman litigation regarding West-Ward’s generic Afinitor® (everolimus 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets)).
  • The Gillette Company v. Dollar Shave Club, Inc., et al., No. 15-1158 (D. Del.) (litigation filed against defendants for infringement of Gillette’s blade coating technology patent, case settled favorably before trial).
  • Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc., No. 1:14-cv-00874 (D. Del.) (Hatch-Waxman litigation regarding Teva’s generic Nasonex® (mometasone inhalation product), case settled favorably after district court decision of non-infringement).
  • Prometheus Laboratories Inc. v. Roxane Laboratories, Inc., et al., No. 2:11-cv-01241 (D.N.J.) (Hatch-Waxman litigation regarding Roxane’s generic Lotronex® (alosetron tablets); district court decision invalidating patent-in-suit affirmed on appeal).
  • Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., et al., No. 10-cv-01376 (S.D. Ind.) (Hatch-Waxman litigation regarding Defendants’ pemetrexed (generic Alimta®) products).
  • Cadence Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC, No. 13-cv-00139 (S.D. Cal.) (Hatch-Waxman litigation regarding Fresenius’s intravenous acetaminophen (generic Ofirmev®) product; settled favorably before trial).
  • Teva Pharmaceuticals USA, Inc. v. Amgen, Inc., No. 09-cv-5675 (E.D. Pa.) (pre-BPCIA litigation regarding Teva’s recombinant granulocyte colony-stimulating factor (rG-CSF) product; settled favorably before trial).
Professional Activities

Mr. Cottler is a member of the American Bar Association, the New York Bar Association and the New York City Bar Association (Patents Committee, 2009-2012 (Secretary); 2014-present).


While attending law school, Mr. Cottler was a senior editor of the Albany Law Review. Mr. Cottler was also a Sponsler Fellow, an Honors Teaching Fellowship program in which second-year students in the top 10 percent of their class are assigned to a section of first-semester Federal Civil Procedure as a teaching fellow.

In The News









J.D., 2006
Albany Law School

(magna cum laude)

B.S., Biological Sciences concentration in Neuroscience, 2002
Cornell University



New York


U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
U.S. Court of Appeals for the Federal Circuit
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique